The BSE said the exchange has sought clarification from Dr Reddys Laboratories on March 21, 2017, with reference to news flashed on ET Now dated March 21, 2017 quoting "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance."
The reply is awaited.
Earlier, on March 9, 2017, the stock of pharmaceutical company hit a low of Rs 2,702 after it said the US drug regulator issued a Form 483 with 13 observations for the company’s formulation manufacturing facility at Duwada, Visakhapatnam.
“The audit of Company's formulation manufacturing facilty at Duwada, Visakhapatnam, by the US FDA, has been completed on March 08, 2017. The Company has been issued a Form 483 with 13 observations, which the Company is addressing,” Dr Reddys Laboratories had said in a BSE filing.
At 10:47 am; the stock was down 4% at Rs 2,630 on BSE as compared to 0.11% decline in the S&P BSE Sensex. The trading volumes on the counter nearly doubled with a combined 858,883 shares changed hands on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)